Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025. Below are several of the best abstracts from Day 3, as chosen by our outstanding faculty.
At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.
Bella Mehta bella_mehta
9 months ago
Disease activity associated with symtomatic knee OA and increased with increased KL grades
Abst#2625 #ACR25 @RheumNow https://t.co/uCrdnVXk0J
Akhil Sood MD, MS AkhilSoodMD
9 months ago
A deep dive into Lupus 🔬
Abstract 2601: Single-cell insights in SLE & pre-clinical autoimmunity
🔹 Plasmablast expansion → high disease activity & SLE risk
🔹 Metabolic activity varies by cell type
🔹 Established disease: ↑ glycolysis & OxPHOS changes
@RheumNow #ACR25
Antoni Chan MD (Prof) synovialjoints
9 months ago
Head to head study of Secukinumab vs Ustekinumab. In TNFi-experienced PsA patients, the AgAIN trial shows secukinumab performed better than ustekinumab in HAQ-DI response (57.1% vs 27.0%, p=0.002) and across all endpoints (joint counts, pain, and skin outcomes). Fewer https://t.co/CDCWkLF5TW
Akhil Sood MD, MS AkhilSoodMD
9 months ago
Abstract 2360: Single-center lupus pregnancy cohort found that:
🔹 Absence of DORIS remission associated w/ adverse pregnancy outcomes (Pre-term, Pre-eclampsia)
🔹 This is along with known risk factors: antihypertensive use, prior nephritis, active disease
@RheumNow #ACR25 https://t.co/STg1NBeFPo
Jiha Lee JihaRheum
9 months ago
CDAI appropriately guided therapy escalation in RA, but not for everyone. Treatment adjustments were less likely in pts with public or no insurance. Even data-driven care can fall short when access barriers persist.
@RheumNow #ACR25 Abstract#2616
Bella Mehta bella_mehta
9 months ago
Reaadmissions in sle pregnancies from 66k patients
Insurance and economics seem to be very important in predictions using machine learning.
Abst#2629 #ACR25 @RheumNow https://t.co/x2oo9TOxoh
David Liew drdavidliew
9 months ago
In healthy women, preeclampsia was more common with:
- increased calprotectin
- decreased anti-CCP (very low levels)
during pregnancy
& this has good predictive capacity for future preeclampsia. Rheum pathophys can give insights into adjacent pathology
#ACR25 ABST2628 @RheumNow https://t.co/7d5YB6n6XJ
Antoni Chan MD (Prof) synovialjoints
9 months ago
In a retrospective TrinetX analysis of 3 year safety outcome in AS, JAKi use was linked to higher mortality and GI bleeding vs TNFi, but lower malignancy risk. Infection rates were similar, with a trend toward more herpes zoster in JAKi users. Abstract#2633 @RheumNow #ACR25 https://t.co/pPY0wpAKA3
Bella Mehta bella_mehta
9 months ago
Anti ccp may be protective for preeclampsia (secondary to NETs)
Abst#2628 @RheumNow #ACR25 https://t.co/n3ge0iIiB0
David Liew drdavidliew
9 months ago
DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario cohort.
We’re getting better at finding a balance with DMARDs that is safe for both mother and baby. Blanket resistance is harmful
#ACR25 ABST2627 @RheumNow https://t.co/oDOpySGS3N
Bella Mehta bella_mehta
9 months ago
Large Canada ICES dataset- DMARD use is not associated with adverse pregnancy outcomes. In pts with RA, SlE and other rheumatic diseases.
Abst#2627 #ACR25 @RheumNow https://t.co/T9Ll1FNjT7
sheila RHEUMarampa
9 months ago
Predictors of retinopathy progression after HCQ discontinued?
In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c
Age - significant assoc'n with progression
✳️monitor toxicity more closely esp in older pts
#ACR25 @RheumNow Abs2444 https://t.co/9rf2RQAgRQ
Aurelie Najm AurelieRheumo
9 months ago
A new IA drug in OA 🚨
Cell therapy of apoptotic PBMCs ENX-CL-05-001
RCT Ph2A moderate to severe OA
134 pts 3 injections vs. PBO
Pain improvement 24%
Better response in people > 60 and more so 65yo
Potential improvement for > 6mo
Safety mainly local reactions to compound https://t.co/m2MZN3i22b
